High‐dose Bendamustine‐<scp>EAM</scp> followed by autologous stem cell rescue results in long‐term remission rates in lymphoma patients, without renal toxicity

Noesslinger, Thomas; Panny, Michael; Simanek, Ralph; Moestl, Michaela; Boehm, Alexandra; Menschel, Elisabeth; Koller, Elisabeth; Keil, Felix

doi:10.1111/ejh.13102

Cited by 14 publications

(20 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…20 In the present study no patients died due to renal toxicity, and the majority of the ARF cases were reversible, as has been previously reported. 16,17,26,27 Identifying factors that indicate patients at risk of ARF such as age over 55 years, a history of previous ARF and the use of concomitant nephrotoxic drugs could stratify patients for ARF risk and adapt supportive care strategy. 20,28 Furthermore, 47% of patients presented with grade III-IV mucositis, which is more frequent than in previous studies on the BEAM regimen.…”

Section: Subgroup Analysismentioning

confidence: 99%

Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers

Hueso

Gastinne

Garciaz

et al. 2020

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

Section: Subgroup Analysismentioning

confidence: 99%

Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers

Hueso

Gastinne

Garciaz

et al. 2020

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…Interestingly, a study conducted by Noesslinger et al found that the majority of patients (33/41) experienced a rise in creatinine within a few days of bendamustine administration. Unlike other studies, no therapeutic intervention was required for any of the patients 14 . However, BeEAM-related nephrotoxicity has been demonstrated to have more severe consequences.…”

mentioning

confidence: 97%

“…Creatinine elevations after bendamusine-containing HDCT administration has led to concerns over renal toxicity. Several studies have documented nephrotoxicity related to BeEAM chemotherapy, ranging from clinicallyinsignificant creatinine rises to dialysis necessitation 6,8,[14][15][16][17] . Interestingly, a study conducted by Noesslinger et al found that the majority of patients (33/41) experienced a rise in creatinine within a few days of bendamustine administration.…”

mentioning

confidence: 99%

BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy

Hahn

Lim

Dusyk

et al. 2021

Sci Rep

View full text Add to dashboard Cite

In many stem cell transplant centres, BCNU, etoposide, cytarabine and melphalan (BEAM) high-dose chemotherapy (HDCT) has been replaced by the more economic and available bendamustine, etoposide, cytarabine, melphalan (BeEAM) regimen. However, there is a paucity of information on the efficacy and safety of BeEAM HDCT. We describe our experience with BeEAM HDCT in terms of safety, efficacy and cost-savings. We compare overall and progression-free survival to a cohort of patients previously transplanted at our institution with the older BEAM regimen. We performed a retrospective chart review of 41 lymphoma patients undergoing BeEAM HDCT at the Royal University Hospital in Saskatoon, Saskatchewan between 2015 and 2019 to elicit regimen safety in the first 100 days post-transplant. Furthermore, we calculated overall and progression-free survival and constructed corresponding Kaplan–Meier curves, comparing the results to a historical cohort of BEAM patients (n = 86). Finally, we conducted an economic analysis using the financials available at our centre’s pharmacy. With regards to BeEAM HDCT, we report a 100-day transplant-related mortality of 2.4%. Additionally, we report acceptable rates of typhlitis (27%), grade III–IV mucositis (4.9%) and grade III–IV nephrotoxicity (2.4%). In terms of overall and progression-free survival, we found no statistical difference between BeEAM and BEAM (p = 0.296; 0.762, respectively). Finally, our economic analysis revealed a net savings of $21,200 CAD per transplant when BeEAM is used in replacement of BEAM. The acceptable safety profile of BeEAM and its comparable efficacy to BEAM are encouraging for the perseverance of this cost-effective HDCT regimen.

show abstract

“…Second, at least two controlled phase II studies 2,3 and one retrospective experience 4 on Benda-EAM prior to ASCT were recently published ( Table 1). Only the retrospective, French study 4 reported a high rate of grade ≥ III ARF.…”

Section: Benda-eam Prior To Asct and Renal Toxicity: Much Ado About Nmentioning

confidence: 99%

Benda‐EAM prior to ASCT and renal toxicity: Much ado about nothing

Isidori¹,

Loscocco²,

Guiducci³

et al. 2019

American J Hematol

View full text Add to dashboard Cite

Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial. BMC Med. 2014; 12:2. 5. Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.

show abstract

High‐dose Bendamustine‐EAM followed by autologous stem cell rescue results in long‐term remission rates in lymphoma patients, without renal toxicity

Abstract: BendaEAM seems to be feasible with a promising response rate and acceptable toxicity.

Cited by 14 publications

References 25 publications

Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers

Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers

BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy

Benda‐EAM prior to ASCT and renal toxicity: Much ado about nothing

Contact Info

Product

Resources

About